We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
Read MoreHide Full Article
Key Takeaways
MED reported a 36.2% revenue dip in Q3 FY25, due to a sharp decline in active OPTAVIA coaches.
MED's active coach count fell 35%, while revenue per coach slipped 1.9%, pressuring the model.
MED expects stabilization by Q4 2025 as rightsizing, Premier plus, EDGE, and digital tools support recovery.
Medifast, Inc. (MED - Free Report) reported a sharp year-over-year revenue decline in the latest quarter, underscoring continued pressure on its coach-driven business model. Reduced coach participation and modestly lower productivity per coach weighed heavily on performance. In the third quarter of fiscal 2025, revenue fell 36.2% to $89.4 million, primarily due to a significant drop in active earning OPTAVIA coaches. The active coach base declined 35% to 19,500, while average revenue per active earning coach decreased 1.9% to $4,585.
To address these challenges, the company implemented rightsizing actions in October aimed at improving margins as growth resumes. Medifast expects coach growth to re-emerge approximately six to nine months after recent initiatives take hold, with revenue growth typically following one to two quarters later. The company anticipates this inflection point to occur in the fourth quarter of fiscal 2025, representing an initial sign of stabilization. At a minimum, management expects growth in revenue per active earning coach within the next six months, signaling early progress toward recovery.
Medifast continues to emphasize the value of personalized coaching, supported by the Premier+ pricing structure and the EDGE leadership program, both of which are designed to enhance coach productivity and stability into 2026. In parallel, ongoing investments in digital platforms—including enhancements to the app and reporting tools—are improving visibility into client progress and coach performance, enabling more targeted and effective engagement.
While near-term results remain challenged, Medifast’s restructuring efforts, renewed focus on coach economics and continued digital investments point to potential stabilization.
Zacks Rundown for MED
Medifast’s shares have lost 15% in the past six months compared with the industry’s decline of 10.4%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.35, lower than the industry’s average of 1.05.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Key Picks
Some better-ranked stocks have been discussed below:
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Monster Beverage Corporation (MNST - Free Report) engages in the development, marketing, sale and distribution of energy drink beverages and concentrates in the United States and internationally. MNST currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for Monster Beverage's current fiscal-year sales and earnings implies growth of 9.6% and 22.8%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 5.5%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural flaunts a Zacks Rank of 1.
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medifast's Third-Quarter Revenue Fell 36%: Is Stabilization Near?
Key Takeaways
Medifast, Inc. (MED - Free Report) reported a sharp year-over-year revenue decline in the latest quarter, underscoring continued pressure on its coach-driven business model. Reduced coach participation and modestly lower productivity per coach weighed heavily on performance. In the third quarter of fiscal 2025, revenue fell 36.2% to $89.4 million, primarily due to a significant drop in active earning OPTAVIA coaches. The active coach base declined 35% to 19,500, while average revenue per active earning coach decreased 1.9% to $4,585.
To address these challenges, the company implemented rightsizing actions in October aimed at improving margins as growth resumes. Medifast expects coach growth to re-emerge approximately six to nine months after recent initiatives take hold, with revenue growth typically following one to two quarters later. The company anticipates this inflection point to occur in the fourth quarter of fiscal 2025, representing an initial sign of stabilization. At a minimum, management expects growth in revenue per active earning coach within the next six months, signaling early progress toward recovery.
Medifast continues to emphasize the value of personalized coaching, supported by the Premier+ pricing structure and the EDGE leadership program, both of which are designed to enhance coach productivity and stability into 2026. In parallel, ongoing investments in digital platforms—including enhancements to the app and reporting tools—are improving visibility into client progress and coach performance, enabling more targeted and effective engagement.
While near-term results remain challenged, Medifast’s restructuring efforts, renewed focus on coach economics and continued digital investments point to potential stabilization.
Zacks Rundown for MED
Medifast’s shares have lost 15% in the past six months compared with the industry’s decline of 10.4%. MED currently carries a Zacks Rank #4 (Sell).
Image Source: Zacks Investment Research
From a valuation standpoint, MED trades at a forward price-to-sales ratio of 0.35, lower than the industry’s average of 1.05.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for MED’s current and next fiscal-year earnings implies year-over-year declines of 158.7% and 5.6%, respectively.
Image Source: Zacks Investment Research
Key Picks
Some better-ranked stocks have been discussed below:
The Vita Coco Company, Inc. (COCO - Free Report) develops, markets and distributes coconut water products under the Vita Coco brand name in the United States, Canada, Europe, the Middle East, Africa and the Asia Pacific. COCO currently flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Vita Coco's current fiscal-year sales and earnings implies growth of 18% and 15%, respectively, from the year-ago reported figures. Vita Coco delivered a trailing four-quarter earnings surprise of 30.4%, on average.
Monster Beverage Corporation (MNST - Free Report) engages in the development, marketing, sale and distribution of energy drink beverages and concentrates in the United States and internationally. MNST currently sports a Zacks Rank #1.
The Zacks Consensus Estimate for Monster Beverage's current fiscal-year sales and earnings implies growth of 9.6% and 22.8%, respectively, from the year-ago actuals. MNST delivered a trailing four-quarter earnings surprise of 5.5%, on average.
United Natural Foods, Inc. (UNFI - Free Report) distributes natural, organic, specialty, produce and conventional grocery and non-food products in the United States and Canada. At present, United Natural flaunts a Zacks Rank of 1.
The Zacks Consensus Estimate for United Natural’s current fiscal-year sales and earnings implies growth of 1% and 187.3%, respectively, from the year-ago reported figures. UNFI delivered a trailing four-quarter earnings surprise of 52.1%, on average.